Associate Professor/Senior Engineer
Zhao Dongdong

Title:Zhao Dongdong

Fax:022-24828783

E-mail:zhao_dd@tib.cas.cn

Research Interest

Development and Application of Genome Editing Technology

Education & Professional Experience

2021-Present, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Associate Investigator

2016-2021, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Assistant Researcher

2014-2016, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Research Intern

2011-2014, China National Research Institute of Food and Fermentation, Master's Degree in Fermentation Engineering

2007-2011, Shandong University, Bachelor's Degree in Biotechnology

Honors and Awards

A member of the Youth Innovation Promotion Association CAS

Selected Publications

1. Zhao D, Li J, Li S, Xin X, Hu M, Marcus A. Price, Susan J. Rosser, Bi C, Zhang X. Glycosylase base editors enable C-to-A and C-to-G base changes. Nature Biotechnology. 2021, 39:35–40.

2. Ye L, Zhao D, Li J, Wang Y, Li B, Yang Y, Hou X, Wang H, Wei Z, Liu X, Li Y, Li S, Liu Y, Zhang X, Bi C. Glycosylase-based base editors for efficient T-to-G and C-to-G editing in mammalian cells. Nature Biotechnology. 2023, 10.1038/s41587-023-02050-w. (co-first author)

3. Zhao D, Jiang G, Li J, Chen X, Li S, Wang J, Zhou Z, Pu S, Dai Z, Ma Y, Bi C, Zhang X. Imperfect guide-RNA (igRNA) enables CRISPR single-base editing with ABE and CBE. Nucleic Acids Research. 2022, 50:4161-4170.

4. Zhao D, Zhu X, Zhou H, Sun N, Wang T, Bi C, Zhang X. CRISPR-based metabolic pathway engineering. Metabolic Engineering. 2021, 63:148-159.

5. Wu Y, Wan X, Zhao D, Chen X, Wang J, Tang X, Li J, Li S, Sun X, Bi C, Zhang X. AAV-mediated base-editing therapy ameliorates the disease phenotypes in a mouse model of retinitis pigmentosa. Nature Communications. 2023, 14:4923. (co-first author)

6. Sun N, Zhao D, Li S, Zhang Z, Bi C, Zhang X. Reconstructed glycosylase base editors GBE2.0 with enhanced C-to-G base editing efficiency and purity. Molecular Therapy. 2022, 30(7),2452-2463. (co-first author)

7. Wang P, Zhao D, Li J, Su J, Zhang C, Li S, Fan F, Dai Z, Liao X, Mao Z, Bi C, Zhang X. Artificial diploid Escherichia coli by a CRISPR chromosome- doubling technique. Advanced Science. 2023, 10 (7). (co-first author)

8. Wang J, Zhao D, Li J, Hu M, Xin X, Price MA, Li Q, Liu L, Li S, Rosser SJ, Zhang C, Bi C, Zhang X. Helicase-AID. A novel molecular device for base editing at random genomic loci. Metabolic Engineering. 2021, 67:396-402. (co-first author)

9. Zhu X, Zhao D, Qiu H, Fan F, Man S, Bi C*, Zhang X*. The CRISPR/Cas9-facilitated multiplex pathway optimization (CFPO) technique and its application to improve the Escherichia coli xylose utilization pathway. Metabolic Engineering. 2017, 43:37-45. (co-first author)

10. Zhao D, Yuan S, Xiong B, Sun H, Ye L, Li J, Zhang X, Bi C. Development of a fast and easy method for Escherichia coli genome editing with CRISPR/Cas9. Microbial Cell Factories. 2016, 15:205.

Project

Two projects funded by the National Natural Science Foundation of China and one subproject under the National Key Research and Development Program.